By Application
Hot products 
-
Mouse Anti-AAV-5 Recombinant Antibody (V2-503416) (CBMAB-V208-1402-FY)
-
Mouse Anti-CCDC6 Recombinant Antibody (CBXC-0106) (CBMAB-C5397-CQ)
-
Mouse Anti-BHMT Recombinant Antibody (CBYY-0547) (CBMAB-0550-YY)
-
Mouse Anti-8-oxoguanine Recombinant Antibody (V2-7697) (CBMAB-1869CQ)
-
Mouse Anti-ARHGDIA Recombinant Antibody (CBCNA-009) (CBMAB-R0415-CN)
-
Mouse Anti-F11R Recombinant Antibody (402) (CBMAB-0026-WJ)
-
Mouse Anti-dsDNA Recombinant Antibody (22) (CBMAB-AP1954LY)
-
Rabbit Anti-AKT3 Recombinant Antibody (V2-12567) (CBMAB-1057-CN)
-
Mouse Anti-BPGM Recombinant Antibody (CBYY-1806) (CBMAB-2155-YY)
-
Rabbit Anti-Acetyl-Histone H3 (Lys36) Recombinant Antibody (V2-623395) (CBMAB-CP0994-LY)
-
Mouse Anti-ATP1B1 Recombinant Antibody (E4) (CBMAB-0463-LY)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0435) (CBMAB-0437-YY)
-
Mouse Anti-BAX Recombinant Antibody (CBYY-0216) (CBMAB-0217-YY)
-
Mouse Anti-CTNND1 Recombinant Antibody (CBFYC-2414) (CBMAB-C2487-FY)
-
Rat Anti-CD34 Recombinant Antibody (MEC 14.7) (CBMAB-C10196-LY)
-
Mouse Anti-ACTG1 Recombinant Antibody (V2-179597) (CBMAB-A0916-YC)
-
Mouse Anti-ALPL Antibody (B4-78) (CBMAB-1009CQ)
-
Mouse Anti-CD8 Recombinant Antibody (C1083) (CBMAB-C1083-LY)
-
Rat Anti-CD63 Recombinant Antibody (7G4.2E8) (CBMAB-C8725-LY)
-
Mouse Anti-CCL18 Recombinant Antibody (64507) (CBMAB-C7910-LY)
Cervical Cancer
Fig.1 Cervical cancer
Cervical cancer is a cancer originated from the cervix. Globally, cervical cancer is the fourth-most common cause of death from cancer among women and fourth-most common cause of cancer. At early stage, typically no symptoms are been found. However, later symptoms may include pelvic pain, vaginal bleeding, or pain during sexual intercourse. While bleeding after sex may not to be treated seriously, it may also reveal the presence of cervical cancer. Human papillomavirus (HPV) infection leads to about 90% of cases, followed by smoking. However, majority of people who have had HPV infections, do not develop cervical cancer. Cervical cancer typically develops from precancerous changes for 10 to 20 years. Around 90% of cervical cancer cases are diagnosed as squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. Some novel prognostic markers, like TBLR1, MicroRNA-497, have been studied recently.
Loading...
Compare
